ReNeuron Group plc

RENE

GB00BF5G6K95

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 14:30:01 05/02/2024 GMT			5-day change	1st Jan Change
3.375 ^GBX	-2.17%		-.--%	-3.57%

06-26	ReNeuron Group plc Announces Change of Registered Office Address	CI
05-31	RENEURON GROUP PLC Announces Termination of John Michael Hawkins as Director	CI

ReNeuron Group plc Announces Resignation of Catherine Isted as Chief Executive Officer

January 03, 2023 at 07:00 am

ReNeuron Group plc announced that Catherine Isted, ACMA, Chief Executive Officer (CEO) has stepped down from her role with immediate effect.

Latest news about ReNeuron Group plc

ReNeuron Group plc Announces Change of Registered Office Address	06-26	CI
RENEURON GROUP PLC Announces Termination of John Michael Hawkins as Director	05-30	CI
ReNeuron administrators in talks with potential investors	05-17	AN
PetroTal buys Peru's Block 131 for USD5.0 million	05-17	AN
ReNeuron Group Reports CFO Resignation	04-17	MT
ReNeuron CFO steps down to pursue other opportunities	04-17	AN
ReNeuron Group plc Announces Resignation of John Hawkins as Chief Financial Officer, Effect from 7 May 2024	04-17	CI
ReNeuron appoints administrators as rescue talks fail	03-20	AN
ReNeuron Group to Appoint Administrators	03-20	MT
ReNeuron warns; Gama Aviation pledges cash return	02-05	AN
ReNeuron Group Suspends Share Trading in London Amid Financial Woes	02-05	MT
ReNeuron Group plc Provides Group Earnings Guidance for the Second Half and Full Year 2024	01-30	CI
ReNeuron interim loss narrows on lower costs; eyes partnerships	11-08	AN
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Revenue GBP157,000	11-08	MT
Earnings Flash (RENE.L) RENEURON GROUP Reports Fiscal H1 Loss GBX-5.00	11-08	MT
ReNeuron Group plc Reports Earnings Results for the Half Year Ended September 30, 2023	11-08	CI
ReNeuron Group Reports In Vivo Data for Exosome Delivery Platform	04/09/23	MT
ReNeuron makes progress on exosome delivery platform	04/09/23	AN
ReNeuron Group plc Auditor Raises 'Going Concern' Doubt	15/06/23	CI
Transcript : ReNeuron Group plc, 2023 Earnings Call, May 25, 2023	25/05/23
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Revenue GBP530,000	25/05/23	MT
Earnings Flash (RENE.L) RENEURON GROUP Posts FY23 Loss GBX-9.50	25/05/23	MT
ReNeuron Group plc Reports Earnings Results for the Full Year Ended March 31, 2023	25/05/23	CI
ReNeuron Group plc Announces New Scientific Advisory Board	03/04/23	CI
FTSE 100 Closes Down 1.1% as Early Year Optimism Runs Into Turbulence	19/01/23	DJ

ReNeuron Group plc is a United Kingdom-based clinical-stage stem cell company. The Company is engaged in the development of stem cell therapies targeting areas of unmet or poorly met medical need. It has developed a stem cell-derived, exosome-based, drug delivery platform with customizable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several exosome producer cell lines, its CustomEX platform can be optimized for specific tissue targets and payloads, leading to improvements in therapeutic outcome and a reduction in off-target effects. It offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalized induced pluripotent stem cell (iPSC) platform, it has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

Sector

Biotechnology & Medical Research

Calendar

10/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
RENEURON GROUP PLC	-3.57%	2.46M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+41.02%	39.84B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.02B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research